| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cocrystal Pharma, Inc.$1.05
-0.01 (-0.94%)
D 31Pipeline Score Overvalued Pharma · Clinical
Market Cap
15.86 M
EPS
-0.73
P/E Ratio
-
Value Trade
79.28 K
SEC Financials
Q1 2026Dilution Risk
Revenue
225.00 K
R&D Expenses
1.37 M
Operating CF
-2.34 M
Total Assets
7.43 M
Total Liabilities
3.31 M
Equity
4.12 M
D/E Ratio
12,345
-6.5 %
Week
-19.01 %
1 Month
16.76 %
3 Month
26.37 %
6 Month
-91.52 %
5 Year
-95.74 %
All Time
Cash Data
Cash Position
4.68 M
Monthly Burn
780.00 K
Runway
4.9 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
112.11 K
52 Week Range
0.86 - 2.67
% held by Insiders
34.27 %
% held by Institutions
5.63 %
Enterprise Value
12.52 M
Total Shares
13.79 M
Short %
1.39 %
Float Shares
10.27 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D31
Pipeline Score $8M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.5x
rNPV / MCap Top 39%
Micro Cap (rank 553 of 905)
Percentile RankCocrystal Pharma, Inc. faces pipeline headwinds (31/100), with $1.2B risk-adjusted pipeline value, led by CDI-31244 in Chronic Hepatitis C (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDI-31244 Small molecule | Chronic Hepatitis C | Phase 2 | NCT03501550 | 21% | $651M | COMPLETED | 12 | - | - | Jun 7, 2019 | - | Apr 28, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CDI-988 | Norovirus | Phase 1 | 2025-08-06 | |||
CDI-988 | Norovirus | Phase 1 | 2025-08-06 | |||
CDI-988 | Norovirus | Phase 1 | 2025-08-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COCP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COCP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
COCP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COCPCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately. He replaces the previous co-CEOs and brings extensive experience in the biopharma sector. The company aims to accelerate its clinical programs for antiviral treatments using its innovative drug discovery platform. Sapirstein's leadership is expected to enhance the company's strategic direction.
Read more →COCPCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Cocrystal Pharma has announced the development of novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza. These inhibitors are designed to target a conserved region of the viral replication enzyme, showing promising in vitro potency against hantavirus. The company aims to address significant unmet medical needs, particularly in light of recent outbreaks.
Read more →COCPCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma has made significant strides in its antiviral pipeline, notably completing enrollment in the Phase 1b challenge study for CDI-988, which targets norovirus. The company received FDA Fast Track designation for this drug, aiming to expedite its development. Additionally, Cocrystal secured initial funding from an NIH grant to support its influenza antiviral program. However, the company reported a net loss of $2.3 million for the first quarter of 2026.
Read more →COCPCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection Ongoing Phase 1b human challenge study with oral, dire
Cocrystal Pharma presented its progress on CDI-988 at ICAR 2026, showcasing its mechanism of action as a treatment for norovirus infection. The drug has received FDA Fast Track designation, reflecting the urgency of addressing norovirus due to its significant health burden. Currently, CDI-988 is in a Phase 1b human challenge study, with the first cohort fully enrolled to assess infectivity. The company aims to demonstrate CDI-988's efficacy both as a preventive measure and a treatment for this prevalent infection.
Read more →COCPCocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Cocrystal Pharma has received FDA Fast Track designation for CDI-988, an oral antiviral aimed at treating and preventing norovirus infections. This designation facilitates accelerated development and regulatory review, allowing for early communication with the FDA. A Phase 1b study is currently underway to evaluate the drug's efficacy in healthy adults. Norovirus causes significant global health and economic burdens, highlighting the need for effective treatments.
Read more →COCPCocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma has reported its 2025 financial results and provided updates on its antiviral drug development programs, particularly focusing on CDI-988, the first oral antiviral candidate for norovirus. The Phase 1b study is currently underway at Emory University, aiming to evaluate the efficacy and safety of CDI-988. Despite challenges in developing effective treatments for norovirus, the company remains optimistic about its potential as a broad-spectrum antiviral.
Read more →COCPFirst Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma has initiated a Phase 1b study for CDI-988, an oral antiviral for norovirus. The study, conducted at Emory University, aims to evaluate CDI-988's efficacy and safety as both a treatment and preventive measure against norovirus infections. With no current approved treatments, this study addresses a significant global health challenge.
Read more →COCPCocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 CDI-988 is the first oral antiviral drug candidate being develo
Cocrystal Pharma's CDI-988, the first oral norovirus protease inhibitor, is set to be presented at the 39th International Conference on Antiviral Research. This potentially groundbreaking antiviral drug, developed for the treatment and prevention of acute gastroenteritis caused by norovirus, will showcase Phase 1 data along with updates from its ongoing Phase 1b study. The absence of approved therapies for norovirus highlights the urgent market need this drug aims to meet, making it a significant step in antiviral research.
Read more →COCPCocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus Subject enrollment expected to begin in Q1 2026 CD
Cocrystal Pharma has received Institutional Review Board (IRB) approval from Emory University School of Medicine to initiate a Phase 1b human challenge study for its antiviral drug CDI-988, intended for the prevention and treatment of norovirus infections. Enrollment for the study is expected to begin in Q1 2026, involving healthy subjects who will be infected with norovirus to assess the drug's efficacy and safety. This represents a significant step forward in addressing a health issue with no currently approved treatments. The initiative follows prior regulatory milestones and highlights Cocrystal's innovative approach to combating norovirus outbreaks.
Read more →COCPCocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Cocrystal Pharma will present at the 21st Emerging Growth Equity Conference hosted by Noble Capital Markets on December 3, 2025. CFO and co-CEO James Martin will discuss the company’s overview and clinical progress. The event is open to interested investors with a special registration discount. A webcast of the presentation will subsequently be available for 90 days on the company’s website, ensuring broader access to the information shared.
Read more →COCPCocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expe
Cocrystal Pharma (Nasdaq: COCP) reported its third quarter financial results for 2025 alongside key developments in its antiviral drug pipeline. The company has received FDA IND clearance to evaluate CDI-988 in a Phase 1b study aimed at both preventing and treating norovirus infections, expected to begin enrollment in Q1 2026. Furthermore, Cocrystal was awarded a NIH SBIR grant to advance its influenza replication inhibitor program. Despite these advancements, past challenges related to trial conduct and viral resistance in influenza treatments remain a concern.
Read more →COCPCocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Cocrystal Pharma has successfully completed a private placement of units, raising $1.03 million by selling 743,024 shares at $1.39 each. The investment, primarily from company directors, reflects strong confidence in the company's future. Additionally, there is potential for $1.83 million more if warrants are fully exercised. The funds will support clinical development and general corporate purposes.
Read more →COCPCocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Cocrystal Pharma has been awarded a $500,000 NIH SBIR Phase I grant to advance its influenza antiviral program. The funding will support the development of a novel oral antiviral candidate targeting influenza A and B. This award highlights the company's innovative drug discovery platform and opens the door for potential Phase II funding. However, there are risks related to funding delays and competition in the antiviral market.
Read more →COCPCocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. will present an overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025. CFO and co-CEO James Martin will lead the presentation, which will include a Q&A session. Investors can register for the event and schedule one-on-one meetings with Mr. Martin during the conference.
Read more →COCPCocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma, Inc. has announced the successful closing of a registered direct offering, raising approximately $4.7 million upfront, with potential additional proceeds of $8.3 million from warrants. The offering was priced at $1.70 per share and aims to bolster the company's working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.
Read more →COCPCocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma, Inc. has announced a registered direct offering of 2,764,710 shares priced at $1.70 each, aiming to raise up to $13 million. The offering includes unregistered warrants that could provide an additional $8.3 million if fully exercised. The proceeds will be used for working capital and general corporate purposes, with the closing expected around September 15, 2025.
Read more →COCPCocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Cocrystal Pharma presented its lead antiviral candidate, CDI-988, at the International Calicivirus Conference. The drug, which targets norovirus, has shown promising results in Phase 1 studies, including a favorable safety profile. The company has received FDA clearance to proceed with a Phase 1b study, marking significant progress in its clinical development.
Read more →COCPCocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
Cocrystal Pharma has received FDA clearance to conduct a Phase 1b challenge study for CDI-988, an oral broad-spectrum protease inhibitor aimed at preventing and treating norovirus infections. This candidate has shown promising preclinical results and is positioned as a potential first antiviral for norovirus. The study is set to begin before the end of 2025.
Read more →COCPCocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Cocrystal Pharma, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. CFO and co-CEO James Martin will provide an overview of the company and will be available for one-on-one meetings with investors. The event will take place at the Lotte New York Palace Hotel and is accessible both in-person and virtually.
Read more →COCPCocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma reported its financial results for Q2 2025, highlighting a net loss of $2.1 million. The company is preparing for a Phase 1b study of its antiviral candidate CDI-988, which has shown promising results against norovirus. With no approved treatments for norovirus, Cocrystal sees a substantial market opportunity. The company also reported a decrease in R&D expenses compared to the previous year.
Read more →COCPCocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
Cocrystal Pharma presented positive Phase 1 results for its pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium. The study demonstrated favorable safety and tolerability across all tested doses, with no severe adverse events reported. CDI-988 is being developed as a potential treatment and prophylaxis for norovirus, addressing a significant unmet medical need.
Read more →COCPCocrystal Pharma to Presents Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9 th International Calicivirus Conference BOTHELL, Wash. (
Cocrystal Pharma announced that its first-in-class norovirus protease inhibitor, CDI-988, will be presented at the 9th International Calicivirus Conference in September 2025. The presentation will detail findings from a Phase 1 study assessing the drug's safety, tolerability, and pharmacokinetics. There are currently no approved treatments for norovirus infection, making CDI-988's development particularly significant in addressing this highly contagious virus. The company's proprietary technology has enabled the design of this promising antiviral candidate.
Read more →COCPCocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Cocrystal Pharma, Inc. announced that its first-in-class norovirus protease inhibitor, CDI-988, will be presented at the 9th International Calicivirus Conference. The presentation will detail the Phase 1 study results, showcasing CDI-988's broad antiviral activity against norovirus strains. The conference, scheduled for September 7-11, 2025, is an essential platform for sharing advancements in norovirus research. Cocrystal aims to develop this promising treatment amid an urgent need for effective norovirus therapeutics.
Read more →COCPCocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference BOTHELL, Wash. (JUNE 5, 2025) - Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease in
Cocrystal Pharma, Inc. has announced that its novel norovirus antiviral, CDI-988, will be presented at the 2025 Military Health System Research Symposium. This broad-spectrum protease inhibitor is being developed as both prophylaxis and treatment for norovirus, a leading cause of acute gastroenteritis. The presentation, led by Dr. Sam Lee, will discuss promising Phase 1 trial results, emphasizing CDI-988's potential to halt infections early, irrespective of viral strain. Cocrystal's proprietary platform technology has enabled this innovative drug's development, aiming to improve health outcomes in military and civilian populations alike.
Read more →COCPCocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain CC-42344 was shown to be highly active against the highly pa
Cocrystal Pharma announced that its investigational drug candidate CC-42344 has shown strong antiviral activity against the highly pathogenic H5N1 avian influenza strain. The virology study indicated that CC-42344 binds effectively to the PB2 protein of the virus, significantly outperforming the reference antiviral Tamiflu. This development comes amidst growing concerns about the H5N1 strain's potential for human-to-human transmission and the associated public health risks. Cocrystal is progressing with clinical evaluations of CC-42344 as a treatment option for both pandemic and seasonal influenza infections.
Read more →COCPCocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference scheduled for June 5, 2025. Management will engage in a fireside chat and welcomes audience questions. Qualified investors will have the opportunity for one-on-one meetings with Cocrystal management through the conference registration platform. A video webcast of the presentation will be available shortly after the event for interested parties.
Read more →COCPCocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against
Cocrystal Pharma reported its first quarter 2025 financial results, highlighting significant advancements in its antiviral drug-development pipeline. Notably, the company’s lead candidate, CDI-988, exhibited broad-spectrum antiviral activity against norovirus variants and is expected to enter human trials. Financially, research and development expenses decreased, reflecting a focus on capital efficiency. Cocrystal remains committed to addressing viral threats while enhancing shareholder value.
Read more →COCPCocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increa
Cocrystal Pharma has announced that its oral antiviral candidate CDI-988 demonstrates potent activity against the emerging norovirus GII.17 variants. The company reported positive results from a Phase 1 study regarding the drug's safety and tolerability and plans to proceed with a human challenge study in 2025. As GII.17 variants become the most prevalent strain, CDI-988's broad-spectrum capability positions it as a promising candidate in preempting and treating norovirus infections.
Read more →COCPCocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that Sam Lee, President and co-CEO, will present a company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on April 23, 2025. This annual event gathers over 700 attendees from various sectors within the life sciences, including investors, research institutions, and entrepreneurs. The conference focuses on discussing significant breakthroughs in life sciences, making it a vital event for networking and showcasing advances in the field.
Read more →COCPCocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs BOTHELL, Wash. (
Cocrystal Pharma, Inc. reported its financial results for 2024 and provided updates on its antiviral drug-development programs. The company plans to initiate a norovirus human challenge study to evaluate the potential treatment and prevention of norovirus infections. Additionally, Cocrystal is advancing its oral PB2 inhibitor, CC-42344, and has reported favorable safety and tolerability results from multiple studies. Despite a net loss of $17.5 million for 2024, the company remains optimistic about its novel antiviral drug compounds.
Read more →COCPCocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
Cocrystal Pharma, Inc. will participate in a fireside chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025. Management will address investors during the live session, and attendees can submit questions and request one-on-one meetings through the presentation's interface. This event is part of Cocrystal's efforts to enhance investor engagement and communication.
Read more →COCPCocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections Data show favorable safety and tolerability wit
Cocrystal Pharma reported promising Phase 1 results for CDI-988, an oral antiviral aimed at treating norovirus and coronaviruses. The drug demonstrated a favorable safety profile at doses up to 800 mg for 10 days, leading to plans for a higher dose cohort and a human challenge study set for 2025. This development could potentially address the unmet need for effective treatments against norovirus infections, which pose significant public health challenges.
Read more →COCPCocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinu
Cocrystal Pharma, Inc. plans to extend its Phase 2a human challenge study of the PB2 inhibitor CC-42344 due to low rates of influenza infection among participants exposed to the H3N2 strain. Despite this challenge, early data indicate that CC-42344 has a favorable safety and tolerability profile, with no serious adverse events reported. The company remains confident in CC-42344's potential as a robust antiviral treatment for seasonal and pandemic influenza. They are preparing a protocol amendment to the UK regulatory agency to facilitate the necessary infection rates for clinical evaluation.
Read more →COCPCocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs BOTHELL, Wash. (
Cocrystal Pharma, Inc. has reported its financial results for the third quarter of 2024 and provided updates on its antiviral drug-development programs. The company anticipates topline results from two clinical studies in the coming months, focusing on their oral PB2 inhibitor CC-42344 for influenza and their oral protease inhibitor CDI-988 for norovirus. While the financial results indicate a net loss, CFO James Martin expressed optimism regarding the company's cash position to support future development plans. Overall, Cocrystal aims to advance its promising antiviral candidates amid the ongoing global health challenges posed by viral infections.
Read more →COCPCocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins The Company's antiviral candidate for seasonal and pandemic
Cocrystal Pharma is advancing its antiviral drug candidates targeting influenza and coronaviruses as the fall flu and COVID season approaches. The company's lead candidate, CC-42344, has demonstrated in vitro activity against avian influenza strains and aims to provide a solution to treatment resistance issues faced by current antiviral drugs. Cocrystal's proprietary technology platform allows for efficient drug development, with Phase 2a study results expected by the end of 2024. The innovative approach may help combat seasonal and pandemic viral threats effectively.
Read more →COCPCocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
Cocrystal Pharma has initiated the multiple-ascending dose (MAD) segment of Phase 1 trials for CDI-988, its oral pan-viral protease inhibitor. This drug aims to treat viral gastroenteritis and COVID-19 by targeting noroviruses and coronaviruses. Preliminary safety and tolerability results from earlier trial phases have been favorable, with no serious adverse events reported. The full evaluation of the drug's effects is expected to take place over the next couple of years as study results are anticipated in late 2024 or early 2025.
Read more →COCPCocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences BOTHELL, Wash. (
Cocrystal Pharma will present its clinical milestones at upcoming investment conferences, emphasizing its near-term developments. Management anticipates topline results from a Phase 2a study on its PB2 inhibitor CC-42344 and a Phase 1 trial for the protease inhibitor CDI-988 in the coming years. The company aims to showcase the promising attributes of its antiviral candidates, particularly against influenza A and norovirus. These presentations are part of Cocrystal's strategy to engage with institutional investors and highlight the potential of its innovative therapies.
Read more →COCPCocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Expects to report topline results in 2025 from Phase 2a influenza A human challenge study wit
Cocrystal Pharma reported its financial results for the second quarter of 2024 and provided updates on its antiviral drug development programs. The company anticipates topline results from its Phase 2a influenza A human challenge study and the Phase 1 study for the broad-spectrum antiviral CDI-988, both expected in late 2024 or early 2025. Cocrystal continues to validate its drug candidates, with new data showcasing CC-42344's efficacy against avian influenza. However, the company also reported a net loss that increased compared to the previous year, raising concerns about financial sustainability.
Read more →COCPCocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor BOTHELL, Wash. (
Cocrystal Pharma has reported positive outcomes from the Phase 1 study of its drug CDI-988, an oral pan-viral protease inhibitor targeting noroviruses and coronaviruses. The single-ascending dose cohorts exhibited favorable safety and tolerability in healthy volunteers, with no serious adverse events recorded. Cocrystal plans to commence the multiple-ascending dose cohorts later this year, aiming to advance CDI-988 as a potential first-in-class antiviral treatment.
Read more →COCPNew Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows BOTHELL, Wash. (
Cocrystal Pharma, Inc. is advancing its broad-spectrum antiviral CC-42344, currently in a Phase 2a clinical trial aimed at combating influenza A, with findings suggesting potential effectiveness against the H5N1 avian influenza strain. Recent studies confirm CC-42344's capability to inhibit the avian PB2 protein linked to this strain, showing promising in vitro results. The company has reported favorable outcomes from earlier trials and anticipates topline results from the ongoing study by late 2024. However, the increasing incidents of H5N1 infections in humans highlight the urgent need for effective treatments as the public health landscape continues to evolve.
Read more →COCPCocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-c
Cocrystal Pharma reported its financial results for Q1 2024, revealing progress in its antiviral drug-development programs. The company anticipates topline results from a Phase 1 study of CDI-988, a potential pan-coronavirus and pan-norovirus oral antiviral, by the second quarter of 2024. Furthermore, they've completed enrollment in a Phase 2a study for CC-42344 and received constructive feedback from the FDA on their clinical trial designs. Plans for new studies, including an inhaled version of CC-42344, are also set for the latter half of 2024.
Read more →COCPEnrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza BOTHELL, Wash. (
Cocrystal Pharma has successfully completed enrollment for a Phase 2a clinical study involving 78 subjects infected with influenza A to evaluate its oral antiviral candidate CC-42344. This novel broad-spectrum antiviral aims to block key steps in viral replication and addresses the urgent need for influenza A treatments. The company received favorable feedback from the FDA for its study protocol and plans for a Phase 1 inhaled formulation study in Australia. Topline results from the Phase 2a study are anticipated later this year.
Read more →COCPCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs FDA feedback following the Company's submission of a Pre-IND briefing package improves clarity on regulatory
Cocrystal Pharma has reported its financial results for 2023 and provided updates on its antiviral drug development programs. The company received positive FDA feedback regarding its Pre-IND briefing, clarifying regulatory requirements for a Phase 2b clinical trial for its PB2 inhibitor, CC-42344. Additionally, it plans to initiate a Phase 1 study for inhaled CC-42344 in 2024, alongside expecting topline results from ongoing studies for both CC-42344 and the dual coronavirus-norovirus candidate, CDI-988. The financial outlook indicates adequate funding for continued operations and upcoming milestones.
Read more →COCPCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (
Cocrystal Pharma has announced the receipt of Pre-IND feedback from the FDA regarding its oral antiviral candidate CC-42344, which is aimed at treating influenza A. This feedback clarifies regulatory requirements for the company's planned Phase 2b trial. Currently, a Phase 2a challenge study is underway in the UK to evaluate safety and viral efficacy, with Phase 1 preparations ongoing in Australia for an inhaled formulation of the drug. Recent preclinical results have indicated CC-42344's effectiveness against multiple strains of influenza A, while also showcasing its safety profile.
Read more →COCPCocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates BOTHELL, Wash. (
Cocrystal Pharma has provided an update on two investigational antiviral candidates, CDI-988 and CC-42344, designed to combat pandemic and seasonal influenza A as well as noroviruses. Preliminary data from ongoing Phase 1 and Phase 2a studies suggest these candidates are well-tolerated and have favorable safety profiles. Cocrystal anticipates reporting topline results for these studies within the year. The candidates were developed using the company's unique structure-based drug discovery platform, targeting critical viral replication mechanisms.
Read more →COCPCocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A BOTHELL, Wash. (
Cocrystal Pharma announced the initiation of the Phase 2a human challenge study for CC-42344, a new oral antiviral targeting pandemic and seasonal influenza A. The trial aims to assess the safety, tolerability, and efficacy of the drug, and follows encouraging results from previous Phase 1 studies. With significant annual influenza-related health costs and widespread cases, this trial is crucial to develop innovative treatments that could mitigate drug resistance issues. The company expects to release topline data from this trial in 2024.
Read more →COCPCocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
Cocrystal Pharma, Inc. highlighted the favorable data of its influenza A antiviral CC-42344 at the World Vaccine Congress West Coast. The company announced the initiation of a Phase 2a human challenge trial for oral CC-42344 in the UK and plans for a Phase 1 trial of inhaled CC-42344 in Australia in 2024. The antiviral exhibits superior activity against various influenza A strains and presents a promising option for treatment and prevention. Cocrystal's proprietary technology is credited for the development of CC-42344, aimed at combating significant pandemic and seasonal strains effectively.
Read more →COCPCocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
Cocrystal Pharma, Inc. will present an overview at the NobleCon 19 conference on December 4, 2023. Chief Financial Officer James Martin noted that the upcoming year will be significant for the company, with data expected from various antiviral drug development programs. Cocrystal is currently enrolling participants in a Phase 1 trial for CDI-988 and preparing to initiate doses in a Phase 2a human challenge trial for CC-42344. A webcast of the presentation will be available on the company's website after the event.
Read more →COCPCocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potentia
Cocrystal Pharma reported its financial results for Q3 2023 and outlined progress in its antiviral drug development programs. The company is currently enrolling participants in a Phase 1 trial for the novel protease inhibitor CDI-988, which targets both coronavirus and norovirus strains. Additionally, they plan to initiate a Phase 2a human challenge trial for the PB2 inhibitor CC-42344 for influenza A treatment. Cocrystal's pipeline aims to address significant unmet medical needs in viral infections.
Read more →COCPCocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
Cocrystal Pharma will present an update on its novel influenza A antiviral CC-42344 at the World Vaccine Congress West Coast on November 28, 2023. The company, led by President Sam Lee, announced recent authorization to initiate a Phase 2a human challenge trial for the oral version of CC-42344 and plans to start a Phase 1 trial for an inhaled formulation anticipated in the first half of 2024. CC-42344 is designed to effectively target various strains of influenza A, showcasing robust antiviral activity in preliminary tests. Following the presentation, further insights and data from the session will be shared through a press release and on the company website.
Read more →COCPCocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 BOTHELL, Wash. (
Cocrystal Pharma has received authorization from the UK MHRA to initiate a Phase 2a human challenge trial for its oral PB2 inhibitor, CC-42344, targeting pandemic and seasonal influenza A. Following positive safety results from a previous Phase 1 trial in Australia, the company aims to commence the trial by the end of 2023. The trial will assess safety and clinical outcomes in influenza-infected subjects, aiming to address the significant global health risks posed by influenza viruses. Cocrystal anticipates that CC-42344's unique profile could contribute significantly to combating influenza.
Read more →COCPCocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
Cocrystal Pharma has commenced a Phase 1 clinical trial for CDI-988, its oral antiviral candidate targeting norovirus and coronavirus. This innovative drug, discovered through a proprietary platform, aims to evaluate safety and tolerability in healthy volunteers. With no approved antiviral treatments for norovirus, CDI-988 presents significant potential to address urgent public health needs. The study's design includes both single and multiple ascending doses, moving towards further clinical development in the upcoming year.
Read more →COCPCocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
Cocrystal Pharma, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The company's management will be available for one-on-one meetings with investors and industry professionals, providing opportunities for in-person and virtual interactions. A webcast of their presentation will be accessible starting September 11 at 7:00 a.m. Eastern time. Cocrystal focuses on developing antiviral therapeutics targeting viruses such as influenza, coronaviruses, and hepatitis C.
Read more →COCPCocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Cocrystal Pharma has reported its financial results for the second quarter of 2023 and provided updates on its antiviral drug development programs. The company is poised to start a Phase 2a trial for its oral PB2 inhibitor CC-42344 aimed at treating influenza A and has selected CDI-988 as its lead candidate in the oral norovirus program. CDI-988 has received clearance from the Australian regulatory agency for evaluation in healthy volunteers, and positive data is expected from ongoing studies. Cocrystal also confirmed its financial stability to continue its operations for the next year.
Read more →COCPCocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
Cocrystal Pharma has selected CDI-988, a novel oral protease inhibitor, for Phase 1 clinical trials targeting norovirus. With no existing approved treatments, CDI-988 aims to address the significant unmet medical need, particularly among vulnerable populations. The compound has demonstrated potent antiviral activity against pandemic norovirus strains in preclinical studies. The study, approved in Australia, will evaluate safety and tolerability while aiming for an effective treatment solution for norovirus-induced gastroenteritis.
Read more →COCPCocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
Cocrystal Pharma, Inc. has gained approval from the Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 clinical study of its oral 3CL protease inhibitor CDI-988, aimed at treating COVID-19. The study will evaluate the drug's safety, tolerability, and pharmacokinetics in healthy volunteers. CDI-988 has demonstrated strong in vitro potency against SARS-CoV-2, as well as a favorable safety profile that supports oral dosing. The company aims to develop effective treatments for various illnesses caused by coronaviruses, leveraging its proprietary drug discovery platform.
Read more →COCPCocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs BOTHELL, Wash. (
Cocrystal Pharma has reported its first quarter 2023 financial results, showcasing advancements in its antiviral drug development programs. Notably, the company has submitted an application to commence a clinical trial for its oral protease inhibitor CDI-988 in Australia. Additionally, preparations are underway for a Phase 2a clinical study of CC-42344 for influenza A, pending UK regulatory approval. Cocrystal has also secured funding through a $4 million private placement to support ongoing operational activities and future milestones.
Read more →COCPCocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
Cocrystal Pharma presented new data regarding its CC-42344 Phase 1 influenza A study at the ISIRV Antiviral Group Conference. The company's President, Dr. Sam Lee, highlighted the promising safety and antiviral efficacy of CC-42344. The drug exhibits strong potential for treating both pandemic and seasonal influenza. Furthermore, a Phase 2a human challenge study is expected to commence in the second half of 2023.
Read more →COCPCocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors BOTHELL, Wash. (
Cocrystal Pharma, Inc. has appointed Fred Hassan to its Board of Directors, increasing the board's membership to six. Hassan, a veteran in the pharmaceutical industry with over 40 years of experience, has also made a $2 million investment in the company. The board anticipates that his expertise will enhance corporate governance and aid in advancing their antiviral therapeutic pipeline. Cocrystal focuses on developing novel antiviral therapies targeting various viruses, including influenza and coronaviruses.
Read more →COCPCocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
Cocrystal Pharma, Inc. will showcase new data from its CC-42344 Phase 1 study at the 7th Annual ISIRV Antiviral Group Conference on May 4, 2023. The presentation will focus on CC-42344, a novel PB2 inhibitor with promising antiviral activity against influenza A. Following this, the company intends to pursue a regulatory submission for a Phase 2a human challenge study expected in the latter half of 2023. The event underscores the company's commitment to advancing its innovative antiviral therapies in the wake of global health challenges.
Read more →COCPCocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules BOTHELL, Wash. (
Cocrystal Pharma has completed a private placement of 2,030,458 shares at $1.97 per share, raising $4 million. The investment was backed by notable figures in the industry, including the company's director, Phillip Frost, and Fred Hassan from Caret Group, indicating strong confidence in Cocrystal's approach to antiviral therapeutics. The company is preparing to begin multiple clinical trials for its influenza and COVID-19 treatments, aiming for near-term milestones in 2023. This funding enhances their financial position and supports ongoing research efforts.
Read more →COCPCocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Cocrystal Pharma has reported its financial results for 2022 and announced updates regarding its antiviral drug development. The company is preparing to initiate clinical trials for its novel oral antiviral candidates targeting influenza A and COVID-19, subject to regulatory approvals. Leadership indicates that cash resources are sufficient to support ongoing operations, yet plans to pursue non-dilutive funding to facilitate further development. The advancement of their antiviral pipeline is seen as a promising opportunity, despite some uncertainties related to regulatory timelines.
Read more →COCPCocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
Cocrystal Pharma, Inc. (Nasdaq: COCP) is set to present an overview at the Virtual Investor Summit on March 29, 2023. James Martin, CFO and co-CEO, highlighted significant advancements in the company's antiviral programs for influenza A, COVID-19, and norovirus. The event aims to inform investors about ongoing developments and milestones. Cocrystal Pharma specializes in developing novel antiviral therapeutics using unique structure-based technologies.
Read more →COCPCocrystal Pharma Announces Participation in Virtual Investor Events
Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced its participation in several virtual investor events, including the J.P. Morgan Healthcare Conference and the Sequire Virtual Biotechnology Conference. Co-CEO and CFO James Martin will discuss the company's market perspective and updates on its antiviral programs. These events aim to enhance investor relations and highlight Cocrystal's innovations in antiviral therapies targeting diseases such as influenza and COVID-19. The interviews and presentations will be available through the ChannelChek platform and other associated channels.
Read more →COCPCocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study. CC-42344 is a broad-spectrum antiviral for the treat
Read more →COCPCocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with CC-42344 for the treatment of pandemic an
Read more →COCPCocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending dose portions of the ongoing Phase 1 study. CC-42344 is a bro
Read more →COCPCocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and seasonal influenza A; remains on track to report topline results in 2022 Announced oral presentation of CC-42344 Phase 1 influenza A data at th
Read more →COCPCocrystal Pharma to Participate in Two Investor Conferences in November
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida Annual Conference: James Martin, CFO and interim co-CEO, will participate in a pane
Read more →COCPCocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus Replication,” which covers the Company’s broad-spectrum oral PB2 inhibitor CC-4234
Read more →COCPEnrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 BOTHELL, Wash. (
Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 Wash. (October 26, 2022) - Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability and p
Read more →COCPCocrystal Pharma to Present at the LD Micro Main Event XV
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral programs and clinical trials at the LD Micro Main Event XV on Wednesday, October 26
Read more →COCPCocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present data from the Company’s Phase 1 influenza A clinical trial with CC-42344 at the World Antiviral Congress 2022 on Friday, D
Read more →COCPCocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2, the virus that causes COVID-19. CDI-988 targ
Read more →COCPCocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m.
Read more →COCPCocrystal Pharma Announces a 1-for-12 Reverse Stock Split
BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s common stock. Cocrystal’s common stock is expected to begin tradin
Read more →COCPCocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and
Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza A Reported pharmacokinetic (PK) data from the
Read more →COCPCocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (CRO), to c
Read more →COCPCocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the single ascending dose portion of a Phase 1 study with
Read more →COCPCocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies t
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, Ma
Read more →COCPCocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones Reported favorable preliminary data from the two initial cohorts in its Phase 1 stud
Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenz
Read more →COCPCocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies
Read more →COCPCocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSIN
Read more →COCPCocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the NobleCon18—Noble Capital Markets’ Eighteenth Annual Investo
Read more →COCPCocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reported preliminary res
Read more →COCPCocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the
Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza A Advanced COVID-19
Read more →COCPCocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and hosted by M-Vest, being held March 28-30, 2022. Those interested in attending th
Read more →COCPCocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered antiviral CC-4234
Read more →COCPCocrystal Pharma to Participate in Upcoming Investment Conferences
BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor Summit Virtual Small & Micro Cap Conference being held March 8-9. Cocrystal senior m
Read more →COCPCocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron Clinical trials with oral progra
Read more →COCPCocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug A
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference
BOTHELL, Wash., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the C
Read more →COCPCocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant Antiviral activity now confirmed against SARS-CoV-2 and all variants
Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron activity now confirmed against SARS-CoV-2 and all variants of concern Omicron, Delta, Alpha, Beta and Gamma Wash. (December 22, 2021) - Cocrysta
Read more →COCPCocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow
BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present a company overview in the Noble Capital Markets Virtual
Read more →COCPCocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stag
Read more →COCPCocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of
Pharma Reports Third Quarter Financial Results and Provides an Update on Development Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study and Phase 1 in 2022 Advance oral
Read more →COCPCocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses
BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respirator
Read more →COCPCocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
FDA’s response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205 BOTHELL, Wash., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the submission of a
Read more →COCPCocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021
BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage company discovering and developing novel antiviral therapeutics, announces that President and co-interim CEO Dr. Sam Lee will present new data
Read more →COCPCocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza
Read more →COCPCocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will present at the 23rd Annual Global Investment Conference being held September 13-15, 202
Read more →COCPCocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates
Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021 COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is advancing Two IND-enabling studies in the COVID-19 program expected to begin in t
Read more →COCPCocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants
BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and
Read more →COCPCocrystal Joins Russell Microcap Index
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coron
Read more →COCPCocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coron
Read more →COCPCocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coron
Read more →COCPCocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox BOTHELL, Wash. (
Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox Wash. (May 28, 2021) - With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away We
Read more →COCPCocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SA
Read more →COCPCocrystal Pharma Announces Closing of $40 Million Bought Deal
BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coron
Read more →COCPCocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
Pharma Announces $40 Million Bought Deal Offering of Common Stock Wash., May 4, 2021 - Cocrystal Pharma, Inc. (Nasdaq: COCP), ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicat
Read more →COCPCocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coron
Read more →COCPCocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or
Read more →COCPCocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX
BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies
BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
Program advances within the agreement’s initial two-year timeframe BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeut
Read more →COCPCocrystal to Present at the 3rd Annual reimagine Health Research Symposium
BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the
Read more →COCPCocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Cap
Read more →COCPCocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces management will present at the H.C. Wainwright Virtua
Read more →COCPCocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnol
Read more →COCPCocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end – – Ongoing Merck collaboration to discover and develop influenza A/B antivira
Read more →COCPCocrystal Pharma Selected to Present at the World Antiviral Conference
BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox and Dr. Sam Lee, have been se
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and deve
Read more →COCPCocrystal Pharma Provides Update on Influenza A Program
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for Phase 1 clinical study in 2021 – BOTHELL, WA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cocrystal
Read more →COCPUnited States District Court DISTRICT OF NEW JERSEY TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC., Case No.: 2:19-cv-16751-KM-JBC Plaintiffs, vs. N
States District Court TRENT NICHOLS and SHARON NICHOLS, derivatively on behalf of COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC., Case No.: 2:19-cv-16751-KM-JBC Plaintiffs, vs. NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO CURRENT COCRYSTAL STOCKHOLDERS ELL
Read more →COCPCocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement. UNITED STATES DISTR
Read more →COCPCocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and d
Read more →COCPCocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares
BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced underwritt
Read more →COCPCocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million BOTHELL, WA
Pharma Increases Previously Announced Bought Deal to $15.0 Million WA, August 26, 2020 - Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that,
Read more →COCPCocrystal Pharma Announces $10.0 Million Bought Deal Offering BOTHELL, WA
Pharma Announces $10.0 Million Bought Deal Offering WA, August 26, 2020 - Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has entered
Read more →COCPCocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral BOTHELL, WA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
Read more →COCPCocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus protease inhibitors (3CL) – BOTHELL, WA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cocrysta
Read more →COCPCocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel ant
Read more →COCPCocrystal Pharma Provides COVID-19 Impact Update on Development Programs
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program – – Collaboration with Merck to discover and de
Read more →COCPCocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action - Expanded license agreement with KSURF further
Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action Expanded license agreement with KSURF further broadens and advances Cocrystal's COVID-19 program - Small molecule t
Read more →COCPCocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors - Work completed over decades of renowned biochemist's career serves as basis for Company's
Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors Work completed over decades of renowned biochemist's career serves as basis for Company's structure-based technology which has demonstrated broad utility in d
Read more →COCPCocrystal Pharma to Present at the April 2020 Virtual Investor Summit
– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session – BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnolo
Read more →COCPCocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020 Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State Univ
Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020 Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation ("KSURF") Continuing collaboration wit
Read more →COCPCocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market BOTHELL, WA
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market 11, 2020 - COCRYSTAL PHARMA, INC. (NASDAQ: COCP) ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, a
Read more →COCPCocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market
BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements wit
Read more →COCPCocrystal Pharma Announces Plans to Advance Coronavirus Program Company has immediately initiated Coronavirus program Leveraging patent rights recently acquired from Kansas State University Research Foundation ("KSURF")
Pharma Announces Plans to Advance Coronavirus Program Company has immediately initiated Coronavirus program Leveraging patent rights recently acquired from Kansas State University Research Foundation ("KSURF") Strong financial position bolsters Company's ongoing research a
Read more →COCPCocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market FEBRUARY 28, 2020 BOTHELL, WA
Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market WA, Feb. 28, 2020 (GLOBE NEWSWIRE) - COCRYSTAL PHARMA, INC. (NASDAQ: COCP) ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral
Read more →COCPCocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with
Read more →COCPCocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to further develop leads and choose clinical candidate - COCRYSTAL PHARMA, INC. (NASDAQ: COC
Read more →COCPCocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals
– Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases, including coronavirus respiratory infections – BOTHELL, WA, Feb. 13, 2020 (GLOBE NEW
Read more →COCPCocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today an
Read more →COCPCOCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING
BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the closing of its registered direct offering with
Read more →COCPCOCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of a registered direct offering with gr
Read more →COCPCocrystal Pharma to Present at the 12th Annual LD Micro Main Event
– Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announc
Read more →COCPCocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – – Preclinical influenza A/B program fully-funded by development and commercialization partner, M
Read more →COCPCocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV
- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector memory CD8+ T cells compared with those who relapsed - - Develop
Read more →COCPCOCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING
BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of an underwritten public offering with
Read more →COCPCOCRYSTAL PHARMA
PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK WA, October 30, 2019 - COCRYSTAL PHARMA, INC. (NASDAQ: COCP) ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announ
Read more →COCPCOCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it intends to offer shares of its common stock for
Read more →COCPCocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting
New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV) Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR) 12, which is considered a cure, using only 6 weeks of Epclusa’s therapy
Read more →COCPCocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses
- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design platform technology - BOTHELL, WA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Read more →COCPCocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., President of Cocrystal, will
Read more →COCPCocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference
- Presentation on Friday, October 4th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced
Read more →COCPCocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable pharmacokinetic and ADMET profiles of PB2 inhibitors - BOTHELL, WA, Sept. 0
Read more →COCPCocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference
BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it will present preclinical data of CC-42344
Read more →COCPCocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure additional strategic partnerships across pipeline – BOTHELL, WA, Aug. 09, 2019
Read more →COCPCocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest HepC virus carrier populations in the world BOTHELL, WA, May 20, 2019 (GLOBE NEWSWIRE
Read more →COCPCocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
– Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 – BOTHELL, WA, May 10, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company disco
Read more →COCPCocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement of important new treatments for influenza – – Clinical development advancement
Read more →COCPCocrystal Pharma Announces Closing of Private Placement BOTHELL, WA
Pharma Announces Closing of Private Placement WA, March 11, 2019 - Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it had entered into binding
Read more →COCPCocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination therapy to include approved HCV DAAs (direct antiviral agents) - Company reports
Read more →COCPCocrystal Announces Board Changes
BOTHELL, WA, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., a biotechnology company with a proprietary technology platform focused on developing medicines to treat viral diseases, today announced changes to its board of directors. Dr. Raymond F Schinazi, who has served
Read more →COCPCocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck BOTHELL, WA
Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck WA, January 3, 2019 - Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that t
Read more →COCPCocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the potential to address high-value areas of unmet medical needs - - Company’s novel, b
Read more →COCPCocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has demonstrated excellent antiviral activity against influenza A strains and shows a favor
Read more →COCPCocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
BOTHELL, WA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influen
Read more →COCPCocrystal Pharma, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc. (f/k/a/ BioZone Pharmaceuticals, Inc.)
Lead Plaintiff Deadline is November 19, 2018 NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- October 24, 2018 - Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of
Read more →COCPCOCRYSTAL PHARMA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc. (f/k/a/ BioZone Pharmaceuticals, Inc.)
Lead Plaintiff Deadline is November 19, 2018 NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against C
Read more →COCPCocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier populations in the world ATLANTA, GA and BOTHELL, WA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cocry
Read more →COCPCOCRYSTAL PHARMA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc. (f/k/a/ BioZone Pharmaceuticals, Inc.)
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc. (f/k/a BioZone Pharmace
Read more →COCPCocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis
Read more →COCPCocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for ultra-short treatment of HCV expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, Aug. 09, 2018 (GLOBE
Read more →COCPCocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developin
Read more →COCPCocrystal Pharma Announces Inclusion in Russell Microcap Index
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis
Read more →COCPCocrystal Pharma Announces Nasdaq Closing Bell Ceremony
ATLANTA, GA and BOTHELL, WA, June 04, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis
Read more →COCPCocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis v
Read more →COCPCocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit
- Presentation on Thursday, May 10 at 11:15 AM PDT - ATLANTA, GA and BOTHELL, WA, May 10, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutic
Read more →COCPCOCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING TUCKER, GA and BOTHELL, WA.
PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING GA and BOTHELL, WA. May 1, 2018 - COCRYSTAL PHARMA, INC. (NASDAQ: COCP), ("Cocrystal" or the "Company") a clinical stage biotechnology company focused on developing innovative antiviral therapeutics, today announced the pric
Read more →COCPCocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical s
Read more →COCPCocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March 22, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal
Read more →COCPCocrystal Pharma Announces Uplist to The Nasdaq Capital Market
ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis
Read more →COCPCocrystal Pharma Provides Update on Reverse Stock Split
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), (“Cocrystal” or the “Company”), a biotechnology compan
Read more →COCPCocrystal Pharma Announces 1-for-30 Reverse Stock Split
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of hepatitis C infection – – Company positioned to achieve clinical and regulatory m
Read more →COCPCocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
ATLANTA, GA and BOTHELL, WA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending September 30, 2017 a
Read more →COCPCocrystal Pharma, HitGen and InterX Enter into Drug Discovery Collaboration
ATLANTA, GA and BOTHELL, WA--(Marketwired - Sep 5, 2017) - Cocrystal Pharma, Inc. (OTCQB: COCP) today announced that it has entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company to develop sm
Read more →COCPCocrystal Pharma Announces Filing 2017 Second Quarter Financial Statements and Provides Company Update
ATLANTA, GA and BOTHELL, WA--(Marketwired - Aug 8, 2017) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending June 30, 2017 and provid
Read more →COCPCocrystal Pharma Receives Investment Through Private Placement
BOTHELL, WA and ATLANTA, GA--(Marketwired - Apr 24, 2017) - On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company") closed on proceeds of $3,000,000 in a private placement offering (the "Offering") of 12,500,000 shares of the Company's common stock at a purchase p
Read more →COCPCocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2016 and Provides Company Update
ATLANTA, GA and BOTHELL, WA--(Marketwired - Apr 3, 2017) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing on Form 10-K of its financial results for the fourth quarter and year ended
Read more →COCPCocrystal Pharma to Present Clinical Data on its Potent Pan-genotypic NS5B Non-nucleoside Inhibitor CC-31244 at the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting
BOTHELL, Wash. and ATLANTA, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it has been selected to give an oral presentation on Saturday, February 18, 201
Read more →COCPPRESENTATION Untitled Document
PRESENTATION Untitled Document
Read more →COCPCocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects ATLANTA, GA and BOTHELL, WA
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects ATLANTA, GA and BOTHELL, WA - April 25, 2016 -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics
Read more →COCPCocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus ATLANTA, GA
Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus ATLANTA, GA-February 10, 2016-Cocrystal Pharma, Inc. (COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today it has
Read more →COCPBIOZONE PHARMACEUTICALS, INC. ACQUIRES BIOZONE LABORATORIES
BIOZONE PHARMACEUTICALS, INC. ACQUIRES BIOZONE LABORATORIES, INC. AND RELATED COMPANIES July 7, 2011; Miami, Florida - BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) announced today that it has acquired all of the outstanding common stock of BioZone Laboratories, Inc.; all of the
Read more →COCPINTERNATIONAL SURF RESORTS, INC. (ISFR) ENTERS BINDING LETTER OF INTENT TO ACQUIRE BIOZONE LABORATORIES COMPANY TO BE RENAMED "BIOZONE PHARMACEUTICALS, INC." AND AUTHORIZES 10:1
INTERNATIONAL SURF RESORTS, INC. (ISFR) ENTERS BINDING LETTER OF INTENT TO ACQUIRE BIOZONE LABORATORIES COMPANY TO BE RENAMED "BIOZONE PHARMACEUTICALS, INC." AND AUTHORIZES 10:1 FORWARD STOCK SPLIT March 2, 2011; Miami, Florida - International Surf Resorts, Inc., (ISFR:OTCBB),
Read more →Competitive Position
How COCP ranks across every disease it competes inCompetitive Position is a premium feature
See how COCP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial